2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.22 Arter

PP01.22 Arter - Poster

Pdf Summary

A recent study by Zhaohui Liao and colleagues at the Chao Family Comprehensive Cancer Center of the University of California Irvine examined the distribution of tumor mutation burden (TMB) among different classes of BRAF mutated Non-Small Cell Lung Cancer (NSCLC). The study utilized data from the AACR GENIE database, focusing on three distinct classes of BRAF mutations in NSCLC. Out of 20,713 NSCLC patients, 1.6% were classified as class I (BRAF V600E/X), 1.3% as class II, and 1.1% as class III. The median TMB levels were found to be 6.5, 9.5, and 10.3 for class I, II, and III respectively, indicating a wide range of TMB distribution among the different classes. Notably, a significant proportion of patients across all classes exhibited a high TMB (>10), with class III showing the highest median TMB levels followed by class II and then class I. The study concludes that there is substantial heterogeneity within each class of BRAF NSCLC, emphasizing the importance of considering TMB levels in treatment decisions for these patients. For further inquiries, the contact email provided is zarter@hs.uci.edu.

Keywords

Zhaohui Liao

Chao Family Comprehensive Cancer Center

University of California Irvine

tumor mutation burden

BRAF mutated Non-Small Cell Lung Cancer

AACR GENIE database

BRAF mutations

NSCLC patients

TMB levels

heterogeneity